Tumor-infiltrating lymphocytes (TIL) were presumed to be enriched for T cells recognizing specific tumor-rejection antigens and as originally envisioned by Rosenberg et al, 9 could potentially be ...

The initiation of T-cell–mediated antitumor immune responses requires the uptake and processing of tumor antigens by dendritic cells and their presentation on MHC-I molecules. Here we show in a ...

The antigens targeted by the host's immune system should be defined and, more importantly, the antigens that mediate tumor rejection should be identified.

In some cases, the identification of tumor-derived epitopes recognized by cytotoxic T lymphocytes led to the identification of specific tumor-rejection antigens.

“In the omics era, we are finding new and attractive cancer vaccine targets, but in some patients we may not know what the most effective tumor rejection antigen is,” says James L. Gulley, M.D ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in ...

The latter finding contrasts with those of our earlier report, in which two organ-transplant recipients with melanoma who were treated with anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) did not ...

Tumor infiltrating lymphocyte (TIL) therapy for cancer treatment, illustration. During TIL therapy, T-cells (blue) that recognize tumor cells (red) are obtained from a patient.

They ended up with 32 antigen candidates, all borne of cancer's alternative RNA splicing, that showed promise as an immunotherapy target, and chose the top four for more rigorous testing.

Regulatory T (Treg) cells can limit the rejection response, and type 17 helper T (Th17) cells can mediate glucocorticoid-resistant rejection. APC denotes antigen-presenting cell, DC donor cell ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...

Immunologists have long searched for tumor-rejection antigens: molecules on tumor cells, but not on normal tissues, that could be recognized by the immune system and would lead the immune system to ...